In December 2024, the FDA affirmed that the tirzepatide shortage had ended, formally barring compounders from producing their knockoff versions of the popular weight-loss drug.
In December 2024, the FDA affirmed that the tirzepatide shortage had ended, formally barring compounders from producing their knockoff versions of the popular weight-loss drug.